Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia

Circulation

Volumn 99, Issue 13, 1999, Pages 1747-1752

  Best, Patricia J M ^a   McKenna, Charles J ^a   Hasdai, David ^a   Holmes Jr , David R ^a   Lerman, Amir ^a  

^a MAYO CLINIC   (United States)

Author keywords

Endothelin; Endothelium derived factors; Hypercholesterolemia; Receptors; Vasculature; Vessels

Indexed keywords

2 PYRIDYLCARBAMIC ACID 2 [[5 (2 METHOXYPHENOXY) 6 [[(4 ISOPROPYLPHENYL)SULFONYL]AMINO] 2 MORPHOLINO 4 PYRIMIDINYL]OXY]ETHYL ESTER; ACETYLCHOLINE; ATRASENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CHOLESTEROL INTAKE; CONTROLLED STUDY; CORONARY RISK; HYPERCHOLESTEROLEMIA; INTRAARTERIAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BLOCKING; SWINE;

EID: 0033528717     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.13.1747     Document Type: Article

References (45)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
2. Bobik A, Grooms A, Millar JA, Mitchell A, Grinpukel S. Growth factor activity of endolhelin on vascular smooth muscle. Am J Physiol. 1990; 258:C408-C415.
3. Sakurai T, Yanagisawa M, Masaki T. Molecular characterization of the endothelin receptors. Trends Pharmacol Sci. 1992;13:103-108.
4. Winkles JA, Alberts GF, Brogi E, Libby P. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun. 1993;191:1081-1088.
5. Tamirisa P, Frishman WH, Kumar A. Endothelin and endothelin antagonism: roles in cardiovascular health and disease. Am Heart J. 1995; 130: 601-610.
6. Mathew V, Cannan CR, Miller VM, Barber DA, Hasdai D, Schwartz RS, Holmes DR Jr, Lerman A. Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation. 1997;96:1930-1936.
7. Seo B, Oemar BS, Siebenmann R, von Segesser L, Luscher TF. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994;89:1203-1208.
8. Hasdai D, Mathew V, Schwartz RS, Smith LA, Holmes DR Jr, Katusic ZS, Lerman A. Enhanced endothelin-B-receptor -mediated vasoconstriction of porcine coronary microvessels in diet-induced hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997;17:2737-2743.
9. Cannan CR, Burnett JC Jr, Lerman A. Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. Circulation. 1996;93:646-651.
10. Lerman A, Webster MW, Chesebro JH, Edwards WD, Wei CM, Fuster V, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation. 1993;88:2923-2928.
11. Hasdai D, Best PJM, Cannan CR, Mathew V, Schwartz RS, Holmes DR Jr, Lerman A. Acute endothelin-receptor inhibition does not attenuate acetylcholine induced coronary vasoconstriction in experimental hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1998;18:108-113.
12. Hasdai D, Lerman A. The atherosclerotic potential of endothelin. Coron Artery Dis. 1995;6:901-904.
13. Dashwood MR, Barker SG, Muddle JR, Yacoub MH, Martin JF. [125I]-endothelin-1 binding to vasa vasorum and regions of neovascularization in human and porcine blood vessels: a possible role for endothelin in intimal hyperplasia and atherosclerosis. J Cardiovasc Pharmacol. 1993; 22(suppl 8):S343-S347.
14. Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy. Hypertension. 1994;24:183-188.
15. Kowala MC, Rose PM, Stein PD, Goller N, Recce R, Beyer S, Valentine M, Barton D, Durham SK. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol. 1995;146:819-826.
16. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (I). N Engl J Med. 1992;326:242-250.
17. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992;326:310-318.
18. Neidhart W, Breu V, Burri K, Clozel M, Hirth G, Klinkhammer U, Giller T, Ramuz H. Discovery of RO 48-5695: a potent mixed endothelin receptor antagonist optimized from bosentan. Bioorg Med Chem Lett. 1997;7:2223-2228.
19. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB, Gehrke LJ, Hernandez SR, Magnuson SR, Marsh KC, Novosad EL, von Geldern TW, Wessale JL, Winn M, Wu-Wong JR. Pharmacological characterization of A-127722: an orally active and highly potent ETa-selective receptor antagonist. J Pharmacol Exp Ther. 1996;276:473-481.
20. McKenna CJ, Burke SE, Opgenorth TJ, Padley RJ, Camdrud LJ, Camrud AR, Johnson J, Carlson PJ, Lerman A, Holmes DR Jr, Schwartz RS. Selective ETA receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model. Circulation. 1998;97:2551-2556.
21. Allain CC, Poon LS, Chan CSL, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470-475.
22. Lerman A, Holmes DR Jr, Bell MR, Garratt KN, Nishimura RA, Burnett JC Jr. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation. 1995;92:2426-2431.
23. Borgeson DD, Grantham JA, Williamson EE, Luchner A, Redfield MM, Opgenorth TJ, Burnett JC Jr. Chronic oral endothelin type A receptor antagonism in experimental heart failure. Hypertension. 1998;31: 766-770.
24. Bell MR, Britson PJ, Chu A, Holmes DR Jr, Bresnahan JF, Schwartz RS. Validation of a new UNIX-based quantitative coronary angiographic system for the measurement of coronary artery lesions. Cathet Cardiovasc Diagn. 1997;40:66-74.
25. Hasdai D, Lerman A. Lessons from coronary flow reserve in clinical practice. In: Beyer R, Keren G, Leon MB, Serruys P, eds. Frontiers in Interventional Cardiology. London, UK: Martin Dunitz Publishers; 1997: 317-328.
26. Mangiafico RA, Malatino LS, Santonocito M, Spada RS, Polizzi G, Tamburino G. Raised plasma endothelin-1 concentrations in patients with primary hypercholesterolemia without evidence of atherosclerosis. Int Angiol. 1996;15:240-244.
27. Hasdai D, Gibbons RJ, Holmes DR Jr, Higano ST, Lerman ST. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation. 1997;96:3390-3395.
28. Berkenboom G, Brekine D, Unger P, Grosfils K, Staroukine M, Fontaine J. Chronic angiotensin-converting enzyme inhibition and endothelial function of rat aorta. Hypertension. 1995;26:738-743.
29. Bennett MA, Hillier C, Thurston H. Endothelium-dependent relaxation in resistance arteries from spontaneously hypertensive rats: effects of long-term treatment with perindopril, quinapril, hydralazine or amlodipine. J Hypertens. 1996;14:389-397.
30. Neuser D, Knorr A, Stasch JP, Kazda S. Mitogenic activity of endothelin-1 and -3 on vascular smooth muscle cells is inhibited by atrial natriuretic peptides. Artery. 1990;17:311-324.
31. Battistini B, Chailler P, D'Orleans-Juste P, Briere N, Sirois P. Growth regulator properties of endothelins. Peptides. 1993;14:385-399.
32. Haak T, Marz W, Jungmann E, Hausser S, Siekmeier R, Gross W, Usadel KH. Elevated endothelin levels in patients with hyperlipoproteinemia. Clin Invest. 1994;72:580-584.
33. Zeiher AM, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: a clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation. 1995;91:941-947.
34. Trachtenberg JD, Sun S, Choi ET, Callow AD, Ryan US. Effect of endothelin-1 infusion of the development of intimal hyperplasia after balloon catheter injury. J Cardiovasc Pharmacol. 1993;22(suppl 8):S355-S359.
35. Burke SE, Lubbers NL, Gagne GD, Wessale JL, Dayton BD, Wegner CD, Opgenorth TJ. Selective antagonism of the ET (A) receptor reduces neointimal hyperplasia after balloon-induced vascular injury in pigs. J Cardiovasc Pharmacol. 1997;30:33-41.
36. Lerman A, Burnett JC Jr. Intact and altered endothelium in regulation of vasomotion. Circulation. 1992;86(suppl III):III-12-III-19.
37. Mathew V, Hasdai D, Lerman A. The role of endothelin in coronary atherosclerosis. Mayo Clin Proc. 1996;71:769-77.
38. Best PJM, Berger PB, Miller VM, Lerman A. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med. 1998;128:285-288.
39. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomas HA, Webb DJ, Rabelink TJ. Blockade of the endothelin-A (Eta) receptor increases endogenous NO generation. Circulation. 1997;96(suppl I):I-348. Abstract.
40. Becker RH, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol. 1991;18(suppl 2):S110-S115.
41. Van Belle E, Vallet B, Auffray JL, Bauters C, Hamon M, McFadden EP, Lablanche JM, Dupuis B, Bertrand ME. NO synthesis is involved in structural and functional effects of ACE inhibitors in injured arteries. Am J Physiol. 1996;270(1 Pt 2):H298-H305.
42. Momose N, Fukuo K, Morimoto S, Ogihara T. Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin. Hypertension. 1993;21(6 Pt 2):921-924.
43. Kawaguchi H, Sawa H, Yasuda H. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J Mol Cell Cardiol. 1990;22:839-842.
44. Clavell AL, Mattingly MT, Stevens TL, Nir A, Wright RS, Aarhus LL, Heublein DM, Burnett JC Jr. Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J Clin Invest. 1996;97:1286-1292.
45. Dockier JE, Massart PE, Hodeige D, Van Mechelen H, Clozel JP, Laloux O, Ketelslegers JM, Charlier AA, Heyndrickx GR. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibitor. Circulation. 1997;96: 1250-1256.